PARMEGGIANI, Francesco
 Distribuzione geografica
Continente #
NA - Nord America 12.988
EU - Europa 8.108
AS - Asia 7.038
SA - Sud America 1.171
Continente sconosciuto - Info sul continente non disponibili 282
AF - Africa 183
OC - Oceania 30
Totale 29.800
Nazione #
US - Stati Uniti d'America 12.633
IT - Italia 4.262
SG - Singapore 2.492
CN - Cina 1.653
BR - Brasile 856
VN - Vietnam 768
DE - Germania 733
UA - Ucraina 629
PL - Polonia 626
HK - Hong Kong 614
GB - Regno Unito 439
FI - Finlandia 381
TR - Turchia 356
BD - Bangladesh 334
FR - Francia 332
RU - Federazione Russa 183
IN - India 181
CA - Canada 174
JP - Giappone 155
AR - Argentina 125
MX - Messico 124
NL - Olanda 118
SE - Svezia 115
ID - Indonesia 113
ZA - Sudafrica 58
IQ - Iraq 54
EC - Ecuador 52
CO - Colombia 47
ES - Italia 46
TH - Thailandia 37
BE - Belgio 33
PH - Filippine 32
AT - Austria 31
MY - Malesia 31
PK - Pakistan 29
RO - Romania 27
UZ - Uzbekistan 27
CZ - Repubblica Ceca 26
AU - Australia 25
CH - Svizzera 25
CL - Cile 24
KE - Kenya 24
VE - Venezuela 23
SA - Arabia Saudita 22
EG - Egitto 19
KR - Corea 18
LT - Lituania 18
IL - Israele 17
TN - Tunisia 17
MA - Marocco 16
NP - Nepal 15
PY - Paraguay 15
AE - Emirati Arabi Uniti 14
PE - Perù 13
PT - Portogallo 13
JM - Giamaica 10
AZ - Azerbaigian 9
BG - Bulgaria 9
DO - Repubblica Dominicana 9
TW - Taiwan 9
AL - Albania 8
CR - Costa Rica 8
IR - Iran 8
JO - Giordania 8
UY - Uruguay 8
DK - Danimarca 7
GR - Grecia 7
HN - Honduras 7
IE - Irlanda 7
OM - Oman 7
BO - Bolivia 6
DZ - Algeria 6
ET - Etiopia 6
KZ - Kazakistan 6
RS - Serbia 6
BY - Bielorussia 5
NG - Nigeria 5
NZ - Nuova Zelanda 5
SK - Slovacchia (Repubblica Slovacca) 5
EU - Europa 4
GT - Guatemala 4
KG - Kirghizistan 4
SN - Senegal 4
TZ - Tanzania 4
BA - Bosnia-Erzegovina 3
CG - Congo 3
CI - Costa d'Avorio 3
GA - Gabon 3
GE - Georgia 3
KW - Kuwait 3
LB - Libano 3
MT - Malta 3
MU - Mauritius 3
MW - Malawi 3
NI - Nicaragua 3
PS - Palestinian Territory 3
QA - Qatar 3
SV - El Salvador 3
TT - Trinidad e Tobago 3
BB - Barbados 2
Totale 29.482
Città #
Singapore 1.573
Ashburn 1.386
Fairfield 1.063
Woodbridge 977
San Jose 790
Jacksonville 662
Houston 660
Warsaw 613
Hong Kong 595
Santa Clara 526
Chandler 499
Beijing 498
Council Bluffs 447
Milan 429
Seattle 418
Wilmington 397
Ann Arbor 396
Cambridge 349
Dallas 292
Munich 274
Rome 267
Izmir 237
Ho Chi Minh City 232
Los Angeles 209
New York 206
Helsinki 195
Nanjing 181
Hanoi 165
Princeton 157
Lauterbourg 140
Tokyo 138
Bologna 131
Boardman 113
Ferrara 112
San Diego 86
Naples 80
São Paulo 77
Bari 71
Mexico City 70
Shenyang 67
Jakarta 64
Shanghai 63
Palermo 59
Orem 57
Dong Ket 54
Toronto 54
Florence 52
Montreal 52
Chicago 51
London 51
Redwood City 50
Hefei 49
Nanchang 48
Jiaxing 47
Turin 44
Brooklyn 43
Turku 43
Chennai 42
Catania 41
Tianjin 41
Changsha 39
Denver 38
Buffalo 37
Verona 37
Da Nang 35
Haiphong 35
Moscow 34
Hebei 32
San Francisco 31
Genoa 30
Johannesburg 30
Atlanta 29
Bremen 29
Phoenix 28
Boston 26
Brussels 26
Dearborn 26
Pescara 26
Frankfurt am Main 25
Padova 25
Poplar 25
Venice 25
Addison 24
Mountain View 24
Stockholm 24
Cagliari 23
Falkenstein 23
Guangzhou 23
Norwalk 23
Philadelphia 22
Tashkent 22
Kunming 21
Ankara 20
Baghdad 20
Charlotte 20
Jinan 20
Kuala Lumpur 20
Tampa 20
Quito 19
Rio de Janeiro 19
Totale 17.838
Nome #
EPIDEMIOLOGIA, DIAGNOSI E TRATTAMENTO DELLA COMPLICANZA NEOVASCOLARE SOTTORETINICA 1.621
La gestione clinica e riabilitativa del paziente ipovedente 987
Ibuprofen oral administration increases the intraocular pressure-lowering effect of latanoprost in patients with primary open-angle glaucoma 755
Fattori di crescita e cellule staminali 617
PATOLOGIE OCULARI IN RELAZIONE CON LE PROBLEMATICHE DELL’IPOVISIONE 573
Improving visual activity using Gabor patch technology in Stargardt disease: a retrospective study 448
Impact of methylenetetrahydrofolate reductase C677T polymorphism on the efficacy of photodynamic therapy in patients with neovascular age-related macular degeneration 373
ESAME DEL PAZIENTE AFFETTO DA IPOVISIONE 327
A novel mutation of BEST1 gene in Best disease 319
Eredo-distrofia tapeto-retinica e miopia degenerativa: variabilità fenotipica familiare in tre pazienti di razza caucasica 310
Psoriatic uveitis is not an exploded myth 281
Torsional phacoemulsification: A pilot study to revise the “harm scale” evaluating the endothelial damage and the visual acuity after cataract surgery 280
Coagulation factor XIIIA (F13A1): Novel perspectives in treatment and pharmacogenetics 279
Comparative assessment of intraocular inflammation following standard or heavy silicone oil tamponade: a prospective study 278
Effect of factor XIII-A G185T polymorphism on visual prognosis after photodynamic therapy for neovascular macular degeneration 275
Mechanism of inflammation in age-related macular degeneration: an up-to-date on genetic landmarks 255
A pilot study to propose a "Harm Scale", a new method to predict risk of harm to the corneal endothelium caused by longitudinal phacoemulsification, and the subsequent effect of endothelial damage on post operative visual acuity 247
Anatomical and functional results of patients with late-stage age-related macular degeneration 6 months after smaller-incision new-generation implantable miniature telescope (SING IMT™) implantation 245
Bilateral isolated acute cataracts in three newly diagnosed insulin dependent diabetes mellitus young patients. 241
Genetic predictors of response to photodynamic therapy 235
RETINOPATIA PIGMENTOSA: INQUADRAMENTO CLINICO E TERAPEUTICO 230
PERDITA ENDOTELIALE DOPO ESTRAZIONE EXTRACAPSULARE DI CATARATTA E FACOEMULSIFICAZIONE IN SITU CON IMPIANTO DI LENTE INTRAOCULARE 229
Diabetic macular edema: Safe and effective treatment with intravitreal triamcinolone acetonide (Taioftal) 227
Carbonic anhydrase inhibitor topical application and optic nerve head blood supply in primary open-angle glaucoma patients 224
Diabetic retinopathy and endothelin system: Microangiopathy versus endothelial dysfunction 213
Inflammatory mediators and angiogenic factors in choroidal neovascularization: pathogenetic interactions and therapeutic implications 205
MicroRNAs as potential biomarkers and innovative therapeutic targets in retinal degenerations 205
Central serous chorioretinopathy: Pathogenesis and management 203
Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an update 196
Identification of novel X-linked gain-of-function RPGR-ORF15 mutation in Italian family with retinitis pigmentosa and pathologic myopia 191
Attualita sulla retinite pigmentosa 187
Aflibercept in wet AMD: specific role and optimal use 186
Novel variants of RPGR in X-linked retinitis pigmentosa families and genotype-phenotype correlation 186
Preferential hyperacuity perimetry: perspectives of self-monitoring of neovascular activity in patients with age-related macular degeneration 176
Effetti della somministrazione topica di clonidina 0,125% e brimonidina 0,2% sulla pressione di perfusione oculare e sugli indici perimetrici in pazienti in pazienti affetti da glaucoma primario ad angolo aperto 175
Pseudodominant inheritance of retinitis pigmentosa in a family with mutations in the Eyes Shut Homolog (EYS) gene 172
Epiretinal membrane in a 12-year-old immunocompetent girl with cytomegalovirus infection 170
Effects of the passive transfer of anti-gB antibodies in a rabbit model of HSV-1-induced keratitis 168
BILATERAL CIRCUMSCRIBED HAEMANGIOMA OF THE CHOROID NOT ASSOCIATED WITH SYSTEMIC VASCULAR SYNDROME. 168
Effects of 0.005% latanoprost and 0.5% timolol on circadian intraocular pressure variations in patients with normal tension glaucoma 167
Multiple strokes in a newborn 167
IMMUNIZZAZIONE PASSIVA CON SIERO POLICLONALE NELLA CHERATITE ERPETICA SPERIMENTALE 165
Effects of acute topical administration of clonidine 0.125%, apraclonidine 1.0% and brimonidine 0.2% on visual field parameters and ocular perfusion pressure in patients with primary open-angle glaucoma 165
Local and systemic inoculation of DNA or protein gB1s-based vaccines induce a protective immunity against rabbit ocular HSV-1 infection 162
One-Year Safety and Performance Assessment of the Argus II Retinal Prosthesis: A Postapproval Study 162
Reproducibility of retinal thickness measurements with retinal thickness analyser in healthy and glaucomatous subjects 158
LA QUALITÀ VISIVA NEI PAZIENTI CANDIDATI AD INTERVENTI DI CHIRURGIA RIFRATTIVA 157
Dexamethasone Implant Produces Better Outcomes than Oral Acetazolamide in Patients with Cystoid Macular Edema Secondary to Retinitis Pigmentosa 156
Intravitreal pegaptanib sodium (Macugen®) for treatment of diabetic macular oedema: A morphologic and functional study 154
Bilateral central serous chorioretinopathy in a patient treated with systemic cortico-steroids for non-Hodgkin lymphoma 154
CONGENITAL ADRENAL HYPERPLASIA DUE TO 21-HYDROXYLASE DEFICIENCY ASSOCIATED WITH BILATERAL KERATOCONUS. 154
TRATTAMENTO DEL PAZIENTE IPOVEDENTE 153
Topical nonsteroidal anti-inflammatory drugs for macular edema 152
Eredo-degenerazioni tapeto-retiniche e cataratta. 152
Inflammaging: should this term be suitable for age related macular degeneration too? 151
Clear cell renal cell carcinoma associated with bilateral atypical acute posterior multifocal placoid pigment epitheliopathy 151
12-month retrospective study and review of photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in age-related macular degeneration 150
Optical coherence tomography imaging in the management of the Argus II retinal prosthesis system 149
Are visual disturbances (Excluding diabetic retinopathy) more common in geriatric dm patients? are they risks factor for the progression of disability? 149
Incidence, Risk Factors and Effect on Outcomes of Microcystic Macular Edema after Pars Plana Vitrectomy for Retinal Detachment 147
Gestione clinica della retinite pigmentosa: up-to.date. 145
BILATERAL NEURORETINITIS IN A 6-YEAR-OLD BOY WITH ACQUIRED TOXOPLASMOSIS. 145
Circadian changes of intraocular pressure and ocular perfusion pressure after timolol or latanoprost in Caucasians with normal-tension glaucoma 142
VEGF Levels in the Aqueous Humor of Patients With Wet AMD Treated With Intravitreal Bevacizumab. 141
Peripheral intrastromal hydration facilitates safe, deep trephination in corneas of irregular thickness 139
The burden of X-linked retinitis pigmentosa (XLRP) on patient experience and patient-reported outcomes (PROs): findings from the EXPLORE XLRP-2 study 138
Choroidal Changes in Myopic Eyes Affected by Choroidal Neovascularization 138
Coagulation gene predictors of photodynamic therapy for occult choroidal neovascularization in age-related macular degeneration 136
Application of artificial intelligence models to predict the onset or recurrence of neovascular age-related macular degeneration 131
Application of artificial intelligence in targeting retinal diseases 131
Predictive role of coagulation-balance gene polymorphisms in the efficacy of photodynamic therapy with verteporfin for classic choroidal neovascularization secondary to age-related macular degeneration 130
Effect of 2% dorzolamide on retinal blood flow: a study on juvenile primary open-angle glaucoma patients already receiving 0.5% timolol. 130
ANOMALIE VASCOLARI RETINICHE NELLA BETA-TALASSEMIA MAJOR 128
X-Chromosome Insight for Targeting Gene Therapy 127
Retinitis pigmentosa and cystoid macular pattern 126
The influence of diclofenac ophthalmic solution on the intraocular pressure lowering effect of 0.005% latanoprost in glaucomatous patients 126
Effetti della somministrazione topica di brinzolamide 1% sulla pressione di perfusione oculare e sugli indici perimetrici in pazienti in pazienti affetti da glaucoma primario ad angolo aperto: studio in acuto 125
Endogenous Aspergillus versicolor endophthalmitis in an immuno-competent HIV-positive patient 124
PATOLOGIE DELL’APPARATO VISIVO 123
Prevalence of factor XIII Val34Leu polymorphism in patients affected by spontaneous subconjunctival hemorrhage 122
MESECTODERMAL LEIOMYOMA EXCLUSIVELY INVOLVING THE POSTERIOR CHOROID. 121
ASSESSING THE COST-EFFECTIVENESS OF SWITCHING FROM A BETA-BLOCKER TO LATANOPROST IN THE TREATMENT OF OCULAR HYPERTENSION 121
null 120
The Impacts of Caregiving for Patients with X-Linked Retinitis Pigmentosa (XLRP): Findings from the EXPLORE XLRP-2 Study 119
Session-by-Session Prediction of Anti-Endothelial Growth Factor Injection Needs in Neovascular Age-Related Macular Degeneration Using Optical-Coherence-Tomography-Derived Features and Machine Learning 119
Retinitis pigmentosa: genes and disease mechanisms 119
Total aniridia after nonperforating trauma of a pseudophakic eye: ultrasound biomicroscopic findings 118
MODIFICAZIONI DELLA FLORA BATTERICA CONGIUNTIVALE, DEL FILM LACRIMALE E DEGLI ANNESSI OCULARI NEI PAZIENTI ACNEICI IN TERAPIA CON ISOTRETINOINA 114
FACOMATOSI 113
Denuded Descemet's membrane supports human embryonic stem cell-derived retinal pigment epithelial cell culture 111
The heterozygous 20210 G/A genotype prevalence in patients affected by central and branch retinal vein occlusion: a pilot study. 109
SSRIs and intraocular pressure modifications. Evidence, therapeutic implications and possible mechanisms 108
Clinical and rehabilitative management of retinitis pigmentosa: up-to-date 108
null 107
Genetic Features of Uveal Melanoma 105
Vitrectomy with macular peeling in eyes with vitreomacular interface disorders and nonexudative age-related macular degeneration 103
null 103
Somministrazione topica di apraclonidina 1,0% e brimonidina 0,2% in pazienti affetti da glaucoma primario ad angolo aperto: effetti sulla pressione di perfusione oculare e sugli indici perimetrici 103
Reading performance in patients with retinitis pigmentosa: a study using the MNREAD charts 103
null 102
Totale 20.805
Categoria #
all - tutte 113.898
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 8.261
Totale 122.159


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.564 0 147 144 65 63 70 94 77 59 131 181 533
2022/20231.468 178 59 70 150 245 203 65 118 182 42 90 66
2023/20241.407 119 134 82 81 92 104 88 91 52 164 134 266
2024/20254.189 194 138 311 179 427 397 253 291 650 485 504 360
2025/202610.547 944 488 936 1.285 1.439 614 1.126 615 917 1.140 589 454
2026/20271.128 531 597 0 0 0 0 0 0 0 0 0 0
Totale 29.800